Shots:

• Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label P-IIIb CASTING study- 75% of patients with RRMS and suboptimal response to prior treatment had no evidence of disease activity 2yrs. after switching to Ocrevus
• The analysis showed the proportion of patients achieving NEDA remained consistently high across all measured patient subgroups. Additionally- patients treated with Ocrevus experienced an improvement in most symptoms measured by SymptoMScreen after 2yrs.
• A 97% treatment persistence for Ocrevus patients at 18mos.- and strong adherence to infusions every 6mos.- was seen in an interim analysis of 1-600+ patients in the ongoing German CONFIDENCE study. OCREVUS is the first and only treatment approved for both RMS and PPMS and now 170-000+ people have been treated with Ocrevus globally in the clinical trial and real-world settings; favorable benefit-risk profile remains consistent over 7yrs.

­ Ref: Roche | Image: Roche